1. Lifetime risk estimates calculated by the Cancer Intelligence Team at Cancer Research UK 2023. (2024) Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/risk-factors#heading-Zero. Zugegriffen: 31. März 2024
2. Russo J, Giri VN (2022) Germline testing and genetic counselling in prostate cancer. Nat Rev Urol 19(6):331–343. https://doi.org/10.1038/s41585-022-00580-7
3. Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, De Santis G, Gillessen S, Grummet J, Henry T, van der Kwast TH, van Leenders GJLH, Mason MD, O’Hanlon S, van Oort IM, Oprea-Lager DE, Ploussard O, Rouvière O, Schoots IG, Stranne J, Tilki D, Wiegel T, Van den Broeck T, Farolfi A, Gandaglia G, Grivas N, Lardas M, Liew M, Linares Espinós E, Willemse P (2024) Prostate Cancer, vol EAU Guidelines. Edn (presented at the EAU Annual Congress Paris 2024. EAU Guidelines Office Arnhem, the Netherlands)
4. Stoll S, Unger S, Azzarello-Burri S, Chappuis P, Graffeo R, Pichert G, Rothlisberger B, Taban F, Riniker S (2021) Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer. Swiss Med Wkly 151:w30038. https://doi.org/10.4414/SMW.2021.w30038
5. Omlin A, Pratsinis,M., Stoll,S., Riniker,S., Hess Soom,J., Förbs,D., Padberg Sgier,B., Azzarello-Burri,S., Rothermundt,C. (2022) Molekulargenetik und Molekularpathologie beim Prostatakarzinom. Swiss Med Forum 2022;22(0102):28–34